SÍNTESE, CARACTERIZAÇÃO E AVALIAÇÃO CITOTÓXICA DE COMPLEXO SEMI-SANDUÍCHE DE RUTÊNIO COM LIGANTE ACILTIOUREIA

Abstract

Inorganic medicinal chemistry is part of a field of science that studies and develops therapeutic agents based on metallic compounds, in which it has been gaining ground after the evident success of its most prominent compound, cisplatin, used in the treatment of cancer. At the same time, several other metallic compounds have applicability in the medical field, promulgating greater interest in exploring the properties of metals for the design of new metallopharmaceuticals. The present research project aims to obtain and characterize a new ruthenium complex with the disubstituted acylthiourea ligand. These binders are of biological interest due to their recognition in medical use. Furthermore, in the context of inorganic chemistry, they have high versatility because they allow the formation of different coordination centers, allowing to obtain different uncoordinated regions to carry out intermolecular interactions with biological targets. The compound of interest, which has the general formula [Ru (η6-p-cymene) (PPh3) (T)] (PF6)], where PPh3 = triphenylphosphine and T = N, N- (diphenyl) -N'- benzoylthiourea, yielding 87.77%. It was characterized by molar conductivity allowing to verify the achievement of a cationic charge complex (+1) due to the proportion of electrolytes 1:1. Through 1H, 13C{1H} and 31P{1H} Nuclear Magnetic Resonance (NMR), as well as two-dimensional analyzes such as Single Quantum Coherence Heteronuclear Spectroscopy (HSQC), Multiple Quantum Coherence Heteronuclear Spectroscopy (HMBC) and Spectroscopy of Quantum Correlation (COZY), it became possible to certify the achievement of the complex of interest with appreciable purity. Its cytotoxicity was evaluated, showing promise with an IC50 value for the breast tumor line (MDA-MB-231) of 1.34 ± 0.19 µM, a value lower than that presented by cisplatin (IC50 = 2.44 µM).